A listing of current leukemia, myelodysplastic syndrome and bone marrow cancer clinical trials available at UNC Lineberger Comprehensive Cancer Center.

Acute Myeloid Leukemia (AML)

Study # Study Title PI
J1651 Phase 2 Study of Azacitidine in Combination With Pembrolizumab in Relapsed/Refractory Acute Myeloid Leukemia (AML) Patients and in Newly Diagnosed Older (≥65 Years) AML Patients Joshua Zeidner, MD
LCCC1522 High Dose Cytarabine Followed by Pembrolizumab in Relapsed/ Refractory AML Joshua Zeidner, MD
TPI-ALV-101 Ph I Study of Alvocidib and Cytarabine/Daunorubicin (7+3) in Patients With Newly Diagnosed Acute Myeloid Leukemia (AML) Joshua Zeidner, MD
TPI-ALV-201

Alvocidib Biomarker-driven Phase 2 AML Study

Joshua Zeidner, MD

Acute Lymphoblastic Leukemia (ALL)

Study # Study Title PI
A041501-CIRB

Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia

Matthew Foster, MD
E1910

Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia

Katarzyna Jamieson, MD
LCCC1541-ATL

Administration of Autologous CAR-T CD19 Antigen With Inducible Safety Switch in Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia

Matthew Foster, MD

Myelodysplastic Syndromes (MDS)

Study # Study Title PI
H3B-8800-G000-101 Phase 1 Trial to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of Splicing Modulator H3B-8800 for Subjects With Myelodysplastic Syndromes, Acute Myeloid Leukemia, and Chronic Myelomonocytic Leukemia Callie Coombs, MD

Other Bone Marrow Cancers

Study # Study Title PI
INCB57643-101 A Phase 1/2, Open-Label, Dose-Escalation/Dose-Expansion, Safety and Tolerability Study of INCB057643 in Subjects with Advanced Malignancies Callie Coombs, MD
CP-MGD006-01 Safety Study of MGD006 in Relapsed/Refractory Acute Myeloid Leukemia (AML) or Intermediate-2/High Risk MDS Matthew Foster MD